Page 372 - Read Online

Salleh et al. J Cancer Metastasis Treat 2020;6:31 I http://dx.doi.org/10.20517/2394-4722.2020.70 Page 9 of 9

asymptomatic population in Taiwan. Hepato-gastroenterol 2006;53:1-4.
37. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, et al. Serum CA 19-9 as a marker of resectability and survival in patients
with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010;17:1794-801.
38. Berger AC, Garcia Jr M, Hoffman JP, Regine WF, Abrams RA, et al. Postresection CA 19-9 predicts overall survival in patients with
pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918.
39. Jawad ZA, Theodorou IG, Jiao LR, Xie F. Highly sensitive plasmonic detection of the pancreatic cancer biomarker CA 19-9. Scientific
Rep 2017;7:1-7.
40. Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, et al. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and
survival. HPB (Oxford) 2020;22:224-32.
41. Bolton NM, Maerz AH, Brown RE, Bansal M, Bolton JS, et al. Multiagent neoadjuvant chemotherapy and tumor response are associated
with improved survival in pancreatic cancer. HPB 2019;21:413-8.
42. van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HW, et al. Added value of CA19-9 response in predicting
resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB 2018;20:605-11.
43. Xu HX, Li S, Wu CT, Qi ZH, Wang WQ, et al. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant
chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology 2018;18:671-7.
44. Choi SH, Park SW, Seong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with
chemoradiotherapy. Radiother Oncol 2018;129:340-6.
45. Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, et al. Carbohydrate antigen 19-9 elevation in anatomically resectable,
early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a
national cancer database study. J Am Coll Surg 2016;223:52-65.
46. Choe JW, Kim HJ, Kim JS, Cha J, Joo MK, et al. Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset
diabetes. Hepatobiliary Pancreat Dis Int 2018;17:263-8.
47. Zheng W, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? a case report in a patient with pancreatic cancer. Clin Adv
Hematol Oncol 2013;11:50-2.
48. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumor Biol
2013;34:3279-92.
49. Lee IK, Kim DH, Gorden DL, Lee YS, Sung NY, et al. Prognostic value of CEA and CA 19-9 tumor markers combined with cytology
from peritoneal fluid in colorectal cancer. Ann Surg Oncol 2009;16:861-70.
50. Molina V, Visa L, Conill C, Navarro S, Escudero JM, et al. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with
suspicion of pancreatic cancer. Tumor Biol 2012;33:799-807.
51. Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for
surgeons. ANZ J Surg 2017; 87:987-92.
52. Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, et al. Trefoil factor(s) and CA19. 9: a promising panel for early detection of
pancreatic cancer. EBioMedicine 2019;42:375-85.